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THE authors demonstrated that in vivo administered L-
carnitine strongly ameliorated the immune response in
both healthy individuals receiving Intralipid and ageing
subjects with cardiovascular diseases, as shown by the
enhancement of mixed lymphocyte reaction. Notably, in
the latter group L-carnitine treatment also resulted
in a significant reduction of serum levels of both
cholesterol and triglycerides. Therefore, the hypothesis is
that L-carnitine supplementation could ameliorate both the
dysregulated immune response and the abnormal lipid
metabolism in several conditions.
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ate) is an essential intracellular constituent in higher
animals which is synthesized from peptide bound
lysine. 1’2 In meat and dairy products, carnitine is
easily and almost completely absorbed, but
endogenous biosynthesis can meet normal metabo-
lic requirements of healthy adults.
3 Almost all the
body stores are in skeletal and cardiac muscles
(98%), whereas liver and extracellular fluids contain
only 1-6% of whole-body carnitine.
4
L-carnitine, the physiological isomer, is a
non-toxic substance with an LDs0 similar to the
LDs0 ofamino acids. However, carnitine esters with
long-chain acyls are significantly more toxic, as
shown for example by palmityl carnitine exhibiting
a 23-fold toxicity with respect to free carnitine,
Carnitine and its derivatives have a key role in
regulating substrate flux and energy balance across
cell membranes. 2’6’7 When the carnitine dependent
mechanisms are impaired fatty acid oxidation is
reduced and triglycerides accumulate, therefore
resulting into both microscopic fatty changes and
impaired hepatic ketogenesis.
9 Carnitine is found in
high concentrations in white blood cells.1 How-
ever, the finding of most elevated carnitine
concentrations in circulating mononuclear cells
first suggested the possibility that carnitine and its
derivatives could modulate the function of immune
cells and prompted us to assay the immuno-
modulant properties of carnitine both in vitro and
in vivo.
(C) 1993 Rapid Communications of Oxford Ltd
Materials and Methods
In vitro studies: L-carnitine was a gift from
Sigma-Tau, Pomezia, Italy. Peripheral blood
mononuclear cells (PBMCs) were obtained from
humans, as described previously.’2
For mitogen driven proliferative assays, PBMCs
were resuspended at the concentration of 2 x 106
cells/ml in RPM1 1640 (Gibco Bio Cult., Paisley,
UK) containing 10% heat-inactivated foetal calf
serum (FCS), 1% L-glutamine, and penicillin/
streptomycin. PBMCs were cultured for 72 h in a
5% COg atmosphere at 37C. Then, the cells were
pulse-labelled with 1/Ci of 3H-thymidine (Amer-
sham, UK) in 20/1 medium 16 h before harvesting
the cultures. The incorporation of H-thymidine
was measured in a liquid scintillation beta counter.
In experiments carried out to evaluate the effects
of Intralipid
(R) (Laboratorien Hausmann AG, St
Gallen, Switzerland) and Intralipid(R) plus L-
carnitine were added at various concentrations to
give a final volume of 60/1 at the beginning of the
cultures.
For the determination of lactate dehydrogenase
(LDH) isoenzyme patterns, PBMCs were incubated
in a 5% COg atmosphere at 37C for 48 h in RPMI
1640 added with 10% FCS and antibiotics (control
samples), with either Intralipid (100 #/ml) alone or
Intralipid plus t-carnitine at various concentrations
(1 and 10#g/ml). Then, PBMCs were freeze-
thawed three times and spun at 3 000 rpm for 10
min. The LDH isoenzymes of the supernatant fluid
were determined by cellulose acetate electrophoresis
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of 5/1 samples for 30 min at 150 V. The areas of
enzyme activity were then shown by histochemical
procedures employing phenazine methosulphate
and tetranitro blue tetrazolium in a sandwich
technique. The electrophoretic pattern was scanned
in a densitometer equipped with an integrator.
Ex vivo studies: Six healthy volunteers were first
treated with Intralipid (20%) for 6 h. Heparinized
(10 U/ml) peripheral venous blood was obtained by
venipuncture before the infusion and then each
hour up to the end of the administration of
Intralipid. Peripheral venous blood was again
obtained 24 h after the end of Intralipid infusion.
The same subjects, after 2 days were treated with
Intralipid plus L-carnitine (1 g/h) for the same time
(6 h). Samples of heparinized venous blood were
obtained as described above.
The ability of each plasma sample to inhibit
mixed lymphocyte reaction (MLR) was tested.
Briefly, purified and washed PBMCs, obtained as
described above from healthy donors, were cultured
in two-way mixed lymphocyte culture where for
each time point triplicate measurements were
performed. Mixtures contained 1 x 106 cells from
each of the two cell donors suspended in RPMI
1640 supplemented with antibiotics and 50%
normal pooled plasma or plasmas (50%) obtained
from the individuals treated with Intralipid and
then with Intralipid plus L-carnitine. After 72 h of
culture, PBMCs were pulse labelled with 3H-
thymidine during the last 8 h of incubation. Then,
the cells were collected into glass fibre filters and
the radioactivity was measured in a beta counter.
The degree of inhibition of the MLR, incubated
with plasma obtained from volunteers treated with
either Intralipid or with Intralipid plus -carnitine,
was expressed as a percentage of MLR incubated
with plasmas collected before the administration of
the drugs.
Ex vivo and in vivo studies" Twenty-three hospitalized
patients, 15 males and eight females (mean age
75.5 8 years) with cardiovascular diseases
(cardiomyopathy, atroventricular block, atrial fibril-
lation, ventricular fibrillation, sick sinus syndrome)
were enrolled into the study. The diagnosis was
supported by both clinical criteria and non-
invasive procedures (electrocardiography, phono-
cardiography, radiology and ultrasound).
The patients were treated with I-carnitine (3 g
i.v. per day for 7 days). Peripheral blood samples
were obtained at day 0 and at the end of the trial.
Intradermal reactions to five recall antigens
(candidine, parotitis, tricophytin, PPD and strepto-
kinase-streptodornase) were tested by using the
Multitest (Merieux Institute) immediately before
and after treatment with L-carnitine.
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Table 1. Effect of Intralipid (R) and Intralipid (R) plus L-carnitine
on PHA-driven PBMC proliferation. The results are shown as
mean cpm ___
standard deviation of triplicate experiments
Intralipid (R) L-carnitine (#g/ml)
(#llml)
0 10
0 57 062__+3441 57 518__+2883 58 623+__3512
25 28 209 __+ 2 994 33 542 __+ 2 098 34 778 -I- 2 741
50 27 362+__2553 31 967+__2531 38 678+__2316"
100 20164__+1537 24 250__+2274 26 250_____1883"
250 4564+__ 625 8750+__ 933* 9893+__1132"
p < 0.01
Total lipaemia was measured by the manual
turbidimetric method with a linearity up tO
1 000mg/dl. Total cholesterol and triglycerides
were measured with an Abbott-UP bichromatic
analyser, by using a colorimetric enzymatic method
and an enzymatic UV method, respectively, both
with a linearity up to 500 mg/dl.
Serum carnitine was measured by the radio-
enzyme method described by McGarry and Foster,TM
with minor modifications as described previously,
is
For the assays ofMLR, either 50% normal pooled
sera (from 60 healthy subjects) or sera from the
patients enrolled into the study were added to the
cell suspensions, using microtitre plates with
flat-bottomed wells. The radioactivity measurement
was performed as above described.
Results and Discussion
The proliferation of mitogen (PHA) driven
PBMCs from healthy individuals was strongly
reduced by lntralipid (Table 1). At Intralipid
concentrations up to 200 #l/ml, this inhibition was
not due to cell death, as shown by PBMC samples
tested for viability by trypan blue dye exclusion at
dierent time points. Above this concentration, the
cell viability was slightly impaired resulting in cell
death of about 20% by the third day of culture (data
not shown). Notably, the immunotoxic eects of
Intralipid were dose-dependent. The addition of
-carnitine at various doses (1 and 10#g/ml)
exhibited a protective effect toward the immuno-
toxic action of Intralipid. Furthermore, the more
marked the inhibition due to Intralipid the
more marked was the restoring action ofL-carnitine.
In fact, at the highest Intralipid doses tested
(250/l/ml) I-carnitine increased thePBMCs incorp
.oration of 3H-thymidine by about 20% (p < 0.001).
The addition of L-carnitine at different doses
indicated that the chance of finding doses
eective under a statistically significant standpoint
increased as the concentration of Intralipid in the
medium was augmented. Overall, these data
suggest that L-carnitine acts via a metabolic pathwayL-carnitine improves immune response and lipid metabolism
more than by exerting a direct immunoenhancing
effect and further evidence was found by
performing the isoenzymatic analysis of LDH in
PBMCs cultured for 48 h. Both control PBMCs and
PBMCs treated with Intralipid plus L-carnitine
contained more LDH1 isoenzyme and more heart
sub-units compared to PBMCs treated with
Intralipid alone (p < 0.01). This finding possibly
reflected a greater aerobic glycolysis, as the LDH1
tissue content has been considered to be propor-
tional to the degree of aerobic metabolism.
Likewise, the LDH pattern of PBMCs treated with
Intralipid alone contained more LDH5, likely
pointing out the anaerobic metabolism of cells
cultured in the presence of the fat emulsion.
In studying ex vivo the effects of Intralipid and
L-carnitine in healthy individuals, a modification of
the two-way MLR for the assessment of the
immunosuppressive activity was employed. The
challenge of plasmas from subjects receiving
Intralipid with lymphocytes from healthy unrelated
donors resulted in a mean 9% inhibition of the
lymphocyte reaction after 1 h from the start of the
infusion. The administration of -carnitine in
conjunction with Intralipid resulted, conversely, in
an increase of the responses (mean 12% after 60
min). Therefore, it resulted that after the first hour
of infusion the total difference between plasmas
from subjects treated with Intralipid and subjects
treated with Intralipid plus I-carnitine was about
21% when tested for immunosuppressive activity of
MLR. This difference decreased to 7% after 24 h,
probably due to host’s adaptative metabolic
mechanisms.
Overall, the in vitro and in vivo studies pointed out
that the immunotoxic action of Intralipid could be
reversed, at least to a certain degree, by adding
-carnitine to PBMC cultures, even at minimal
concentrations. Since a direct immunoenhancing
effect of L-carnitine was ruled out, in the authors’
opinion the most probable hypothesis is that
-carnitine could restore the immune response by
removing some metabolic cofactor limitation of
PBMCs cultured in the presence of Intralipid.
The treatment of elderly patients suffering from
cardiovascular diseases with L-carnitine (3 g per day
for 7 days) resulted in a significant reduction of
lipaemia, cholesterolaemia, and triglyceridaemia in
the majority of cases (Table 2). Furthermore, this
result was paralleled by both an increase, in vivo, in
the delayed hypersensitivity response to common
recall antigens (candidine, tricophytin, parotitis,
PPD, streptokinase-streptodornase) and in the
ability of serum to stimulate MLR (Table 3).
Notably, skin test reactivity increased in the same
patients in whom a reduction of serum lipid levels
was observed following -carnitine treatment.
Similarly, MLR was increased when the cells were
Table 2. Serum levels of cholesterol (normal range" 160-330
mg/dl) and triglycerides (normal range: 40-160 mg/dl) before
(A) and after (B) L-carnitine supplementation in ageing patients
with cardiovascular diseases
Patient Cholesterol Triglycerides
A B A B
231 212 138 130
2 279 235 168 145
3 288 231 171 164
4 197 199 143 144
5 281 243 177 169
6 121 156 168 112
7 200 203 136 135
8 157 150 140 114
9 181 251 184 281
10 191 155 112 109
11 231 196 117 117
12 163 175 75 83
13 199 164 114 108
14 175 180 106 106
15 269 198 134 132
16 215 187 176 122
17 152 136 163 124
18 175 110 116 113
19 230 242 114 126
20 176 183 98 106
21 157 136 87 85
22 196 177 126 109
23 226 185 130 130
Table 3. Delayed hypersensitivity skin test and mixed
lymphocyte reactions (MLR) before (A) and after (B)
L-carnitine supplementation in ageing patients with cardio-
vascular diseases
Patient Skin tests M LR
A B % variation
+ +++ +14
2 + ++ +19
3 +++ ++++ +12
4 ++ ++ -3
5 + ++ +21
6 + +++ +35
7 +++ ++ 0
8 ++ +++ +16
9 -12
10 + ++ +9
11 + +23
12 0




17 + ++ +16





23 + ++ +10
+ >5mm < 10mm" ++ >10mm < 15mm; +++
>15 mm.
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added to or preincubated with post-treatment sera
obtained from the same patients, compared to the
results obtained by using the pre-treatment sera.
Patients exhibiting no effect to I-carnitine admin-
istration in lowering blood lipid levels also had
unmodified or even reduced skin test reactivity to
recall antigens. Their sera were also unable to
increase MLR. The general trend in this study was
towards a lowering of lipaemia, cholesterolaemia,
and triglyceridaemia and in enhanced host immune
responsiveness following -carnitine supplementa-
tion. The possibility that -carnitine had a direct
immunoenhancing property was ruled out by
finding that high levels of serum -carnitine were
associated with unchanged immunological para-
meters in patients exhibiting no reduction of blood
lipids following -carnitine treatment.
In conclusion, the above experiments suggest a
direct relationship between L-carnitine, lipids and
immune responsiveness. The mechanisms account-
ing for the effects of L-carnitine on human
lymphocytes in the presence of a lipidic dysmeta-
bolism have yet to be fully established.
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